Cost-effectiveness analysis of lung cancer screening with low-dose computed tomography in an Iranian high-risk population

1. Yousefi, M, Nahvijou, A, Sari, AA, et al. Mapping QLQ-C30 onto EQ-5D-5L and SF-6D-V2 in patients with colorectal and breast cancer from a developing country. Value Health Reg Issues 2021; 24: 57–66.
Google Scholar | Crossref | Medline2. Nahvijou, A, Safari, H, Yousefi, M, et al. Mapping the cancer-specific FACT-B onto the generic SF-6Dv2. Breast Cancer 2021; 28: 130–137.
Google Scholar | Crossref | Medline3. Yousefi, M, Safari, H, Sari, AA, et al. Assessing the performance of direct and indirect utility eliciting methods in patients with colorectal cancer: EQ-5D-5L versus C-TTO. Health Serv Outcomes Res Method 2019; 19: 259–270.
Google Scholar | Crossref4. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline5. Pesch, B, Kendzia, B, Gustavsson, P, et al. Cigarette smoking and lung cancer – relative risk estimates for the major histological types from a pooled analysis of case–control studies. Int J Cancer 2012; 131: 1210–1219.
Google Scholar | Crossref | Medline | ISI6. Roshandel, G, Ghanbari-Motlagh, A, Partovipour, E, et al. Cancer incidence in Iran in 2014: results of the Iranian national population-based cancer registry. Cancer Epidemiol 2019; 61: 50–58.
Google Scholar | Crossref | Medline7. Mir, H, Seyednejad, F, Jalilian, H, et al. Cost of lung cancer in east Azerbaijan province, in Iran, in 2017. Int J Pharm Healthcare Market 2020; 14: 461–470.
Google Scholar | Crossref8. Cressman, S, Peacock, SJ, Tammemägi, MC, et al. The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency. J Thorac Oncol 2017; 12: 1210–1222.
Google Scholar | Crossref | Medline9. Shmueli, A, Fraifeld, S, Peretz, T, et al. Cost-effectiveness of baseline low-dose computed tomography screening for lung cancer: the Israeli experience. Value Health 2013; 16: 922–931.
Google Scholar | Crossref | Medline10. Książek, J, Dziedzic, R, Jelitto-Górska, M, et al. Pilot Pomeranian lung cancer screening program – preliminary report. Ann Acad Med Gedan 2009; 39: 73–82.
Google Scholar11. Sobue, T, Moriyama, N, Kaneko, M, et al. Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol 2002; 20: 911–920.
Google Scholar | Crossref | Medline | ISI12. Thao, M. The cost effectiveness of screening for early stage lung cancer and the testing and treatment of molecular subgroups among non-small cell lung cancer patients in the province of Ontario, Canada. PhD Thesis, University of Toronto (Canada), https://central.bac-lac.gc.ca/.item?id=TC-OTU-68315&op=pdf&app=Library&oclc_number=1033009972 (2014, accessed 7 May 2021).
Google Scholar13. de Koning, HJ, van der Aalst, CM, de Jong, PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020; 382: 503–513.
Google Scholar | Crossref | Medline14. Evans, W, Flanagan, W, Miller, A, et al. Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration. Curr Oncol 2016; 23: e179–e187.
Google Scholar | Crossref | Medline15. Toyoda, Y, Nakayama, T, Kusunoki, Y, et al. Sensitivity and specificity of lung cancer screening using chest low-dose computed tomography. Br J Cancer 2008; 98: 1602–1607.
Google Scholar | Crossref | Medline | ISI16. Ameri, H, Safari, H, Yousefi, M, et al. Interim value set for the EQ-5D-5L in Iran using the crosswalk method. Med J Islam Repub Iran 2020; 34: 121.
Google Scholar | Medline17. Tramontano, AC, Schrag, DL, Malin, JK, et al. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the cancer care outcomes research and surveillance (CanCORS) study. Med Decis Making 2015; 35: 371–387.
Google Scholar | SAGE Journals | ISI18. Brodersen, J, Voss, T, Martiny, F, et al. Overdiagnosis of lung cancer with low-dose computed tomography screening: meta-analysis of the randomised clinical trials. Breathe 2020; 16: 200013.
Google Scholar | Crossref | Medline19. Blom, EF, Ten Haaf, K, de Koning, HJ. Trends in lung cancer risk and screening eligibility affect overdiagnosis estimates. Lung Cancer 2020; 139: 200–206.
Google Scholar | Crossref | Medline20. Woods, B, Revill, P, Sculpher, M, et al. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health 2016; 19: 929–935.
Google Scholar | Crossref | Medline21. Wisnivesky, JP, Mushlin, AI, Sicherman, N, et al. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest 2003; 124: 614–621.
Google Scholar | Crossref | Medline | ISI22. Marshall, D, Simpson, KN, Earle, CC, et al. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001; 32: 227–236.
Google Scholar | Crossref | Medline | ISI23. Kanarkiewicz, M, Szczęsny, TJ, Krysiński, J, et al. Cost-effectiveness analysis of lung cancer screening with low-dose computerised tomography of the chest in Poland. Contemp Oncol 2015; 19: 480–486.
Google Scholar24. Mahadevia, PJ, Fleisher, LA, Frick, KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003; 289: 313–322.
Google Scholar | Crossref | Medline | ISI25. Manser, R, Dalton, A, Carter, R, et al. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. Lung Cancer 2005; 48: 171–185.
Google Scholar | Crossref | Medline | ISI26. Goulart, BH, Bensink, ME, Mummy, DG, et al. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012; 10: 267–275.
Google Scholar | Crossref | Medline | ISI27. Pyenson, BS, Sander, MS, Jiang, Y, et al. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff 2012; 31: 770–779.
Google Scholar | Crossref28. Snowsill, T, Yang, H, Griffin, E, et al. Low-dose computed tomography for lung cancer screening in high risk populations: a systematic review and economic evaluation. Health Technol Assess 2018; 22: 1–276.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif